Study Overview: Bristol-Myers Squibb is conducting a Phase 3 trial titled Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or ...

Discover Piper Sandler's latest biotech oncology picks, ratings, and price targets. Gain expert insights on CGON, BCAX, DAWN, ...

Stage-4 cancer patients are living longer, challenging the idea of what it means to have and survive cancer. “The science just needs to stay a step ahead of me” ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

The Evolving Heritage Gala is a celebration of Black Women in the UK, Africa, and Its Diaspora, honouring the remarkable ...

Repotrectinib has picked up three breakthrough designations from the FDA, including most recently for ROS1-positive metastatic NSCLC patients who have been previously treated with one ROS1 TKI and ...

The study “continues to confirm that RET fusions are clinically targetable alterations, placing them in the company of activating EGFR/ALK/ROS1 alterations,” said Drilon.

Bristol-Myers Squibb Company announced a significant update on their Phase 3 lung cancer trial. The study tests two promising ...

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective ...

This is the repository for the Schunk SVH ROS2 driver. It completes the standalone library with everything that you need to operate the five finger hand in a ROS2 context.

Note that this branch contains the ROS1 implementation for the packages. If you are looking for the ROS2 version, you should go to the ros2 branch ...